Amendment: SEC Form SCHEDULE 13D/A filed by Vicarious Surgical Inc.
$RBOT
Industrial Specialties
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
|
Vicarious Surgical Inc. (Name of Issuer) |
Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) |
92561V208 (CUSIP Number) |
Rebecca Lucia
c/o Innovation Endeavors, 1845 El Camino Real
Palo Alto, CA, 94306
(650) 644-6822
c/o Innovation Endeavors, 1845 El Camino Real
Palo Alto, CA, 94306
(650) 644-6822
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
04/02/2026
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP Number(s): | 92561V208 |
| 1 |
Name of reporting person
Innovation Endeavors III LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
221,038.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
3.4 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP Number(s): | 92561V208 |
| 1 |
Name of reporting person
Dror Berman | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
221,038.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
3.4 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
HC, IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Class A Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
Vicarious Surgical Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
78 Fourth Avenue, Waltham,
MASSACHUSETTS
, 02451. | |
Item 1 Comment:
This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on September 28, 2021 (the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D set forth the aggregate number of shares of Class A common stock and percentages of the shares of Class A common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon 6,470,228 shares of Class A common stock outstanding as of March 16, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on March 23, 2026.
The Reporting Persons' beneficial ownership of the Issuer's securities includes 221,038 shares of Class A common stock directly held by Innovation Endeavors. Mr. Berman is a managing partner at Innovation Endeavors and shares voting and investment authority over the shares held by Innovation Endeavors. | |
| (b) | Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D set forth the number of shares of Class A common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference. | |
| (c) | Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
On March 20, 2026, Innovation Endeavors sold an aggregate of 10,774 shares in open market transactions at prices ranging from $1.05 to $1.11 (weighted average sales price of $1.06 per share).
On March 23, 2026, Innovation Endeavors sold an aggregate of 25,000 shares in open market transactions at prices ranging from $1.00 to $1.05 (weighted average sales price of $1.00 per share).
On March 24, 2026, Innovation Endeavors sold an aggregate of 1,001 shares in open market transactions at prices ranging from $0.95 to $1.00 (weighted average sales price of $0.95 per share).
On March 25, 2026, Innovation Endeavors sold an aggregate of 25 shares in an open market transaction at a price of $1.00 per share.
On March 26, 2026, Innovation Endeavors sold an aggregate of 3,013 shares in open market transactions at prices ranging from $0.85 to $1.00 (weighted average sales price of $0.91 per share).
On March 27, 2026, Innovation Endeavors sold an aggregate of 1,000 shares in open market transactions at prices ranging from $0.70 to $0.72 (weighted average sales price of $0.70 per share).
On March 30, 2026, Innovation Endeavors sold an aggregate of 4,595 shares in open market transactions at prices ranging from $0.80 to $0.81 (weighted average sales price of $0.80 per share).
On March 31, 2026, Innovation Endeavors sold an aggregate of 1,449 shares in open market transactions at prices ranging from $0.71 to $0.83 (weighted average sales price of $0.76 per share).
On April 1, 2026, Innovation Endeavors sold an aggregate of 1,487 shares in open market transactions at prices ranging from $0.65 to $0.88 (weighted average sales price of $0.80 per share).
On April 2, 2026, Innovation Endeavors sold an aggregate of 53,868 shares in open market transactions at prices ranging from $0.72 to $0.83 (weighted average sales price of $0.78 per share).
On April 6, 2026, Innovation Endeavors sold an aggregate of 136,682 shares in open market transactions at prices ranging from $0.78 to $0.85 (weighted average sales price of $0.82 per share).
| |
| (d) | No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons. | |
| (e) | The Reporting Persons ceased to be the beneficial owners of more than five percent of the Class A common stock on April 6, 2026. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Reporting Persons' Schedule 13D filed with the SEC on September 28, 2021). | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|